

Communicable Diseases and Immunization Service 655 West 12th Avenue Vancouver, BC V5Z 4R4

Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca

Date: November 19, 2021 Administrative Circular: 2021:46

ATTN: Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

• 'Pediatric populations – 5 to 11 years of age (inclusive)' has been added.

Please remove page numbers: 1-2 dated November 15, 2021 Please add new page numbers: 1-2 dated November 19, 2021

COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech) (Adult/Adolescent)

- The product name has been updated to differentiate from the pediatric formulation.
- Doses and Schedules: Footnote A has been revised to indicate that the minimum age for vaccine receipt is based on age at presentation (i.e., the Pfizer COVID-19 vaccine adult/adolescent formulation may be offered to individuals on or after their 12th birthday).

Please remove page numbers: 1-6 dated November 12, 2021 Please add new page numbers: 1-6 dated November 19, 2021

COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech) (Pediatric)

This new product page has been added.

Please add new page numbers: 1-5 dated November 19, 2021

COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

Adverse Events has been updated to include rare cases of Guillain-Barré Syndrome.

Please remove page numbers: 1-4 dated November 12, 2021 Please add new page numbers: 1-4 dated November 19, 2021





COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

Adverse Events has been updated to include rare cases of Guillain-Barré Syndrome.

Please remove page numbers: 1-4 dated November 12, 2021 Please add new page numbers: 1-4 dated November 19, 2021

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated November 2021 and replace with the enclosed updated Title Page and Table of Contents dated November 19, 2021.

Supporting resources:

Guidance Document on the Management of Inadvertent Vaccine Errors

Content has been added to address the management of potential inadvertent vaccine errors related to booster doses, as well as the Pfizer-BioNTech COVID-19 Vaccine Pediatric formulation (10 mcg).





BC Centre for Disease Control Provincial Health Services Authority

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM

Medical Director

Communicable Diseases & Immunization Service

BC Centre for Disease Control

with bours

pc:

Provincial Health Officer

Dr. Bonnie Henry

Dr. Reka Gustafson

Vice President, Public Health &

Wellness, PHSA & Deputy Provincial

Health Officer

Deputy Provincial Health Officer

Dr. Martin Lavoie

BC Ministry of Health, Population &

Public Health Division:

Brian Sagar

Senior Director Communicable

Disease, Population and Public Health

Division

Bernard Achampong

Executive Director,

Public Health, Planning and Prevention,

Population and Public Health Division



